Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer

Gynecologic Oncology

Volumn 86, Issue 3, 2002, Pages 274-278

  Bruchim, Ilan ^a,b   Altaras, Marco ^a,b   Fishman, Ami ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemotherapy; Elderly patients; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DRUG RESPONSE; EPITHELIUM; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036446862     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6759     Document Type: Article

References (18)

1. Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S. Age as a prognostic factor in ovarian carcinoma. Cancer 1993;71:606-14.
2. Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Burke TW, Morris M, Kavanagh JJ, Warner D, Wharton JT. Age contrast in patients with advanced epithelial ovarian cancer. Cancer 1993;71:638-43.
3. Markman M, Lewis JL, Saigo P, Rubin S, Jones W, Reichman B, Curtin J, Barakat R, Almadrones L, Morrissey T, Hoskins W. Impact of age on survival of patients with ovarian cancer. Gynecol Oncol 1993;49:236-9.
4. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer 1994;74:2208-14.
5. Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R, Hartenbach EM, Beargen R. Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer. A Gynecologic Oncology Group Trial (GOG 158). Proc ASCO, Abstract 1373, 1999.
6. Reis LG. Ovarian cancer - Survival and treatment differences by age. Cancer 1993;71:524-9.
7. Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994;74: 2101-6.
8. Oriel LG, Hartenbach EM, Remington OL. Trends in United States ovarian cancer mortality, 1979-1995. Obstet Gynecol 1999;93:30-3.
9. Yanick R, Gloeckler Ries L, Yates JW. Ovarian cancer in the elderly: An analysis of SEER program data. Am J Obstet Gynecol 1984;154: 639-47.
10. McGowan L. The management of elderly patients with gynecologic cancer. Curr Opin Obstet Gynecol 1995;7:53-6.
11. Yanick R, Havlik RJ, Wesley MN, Ries L, Long S, Rossi W, Edwards BK. Cancer and comorbidity in older patients: A descriptive profile. Ann Epidemiol 1996;6:399-412.
12. Weintraub NT, Freedman ML. Gynecologic malignancies of the elderly. Clin Geriatr Med 1987;3:669-94.
13. Hightower RD, Nguyen HN, Averette HE, Hoskins W, Harrison T, Steren A. National survey of ovarian carcinoma IV: Patterns of care and related survival for older patients. Cancer 1994;73:377-83.
14. Conte PF, Romanini A, Brunetti I, Giannessi P, Fanucchi A, Gadducci A. Ovarian cancer in elderly women. Int J Gynecol Cancer 1997;7:23-6.
15. Higgins RV, Naumann RW, Gardner J, Hall JB. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin? Gynecol Oncol 1999;75:464-7.
16. Bicher A, Sarosy G, Kohn E, Adamo D, Davis P, Jacob J, Chabner BA, Reed E. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 1993;71:594-600.
17. Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM. Treatment of ovarian carcinoma in the elderly. Gynecol Oncol 1993;49:86-91.
18. Yanick R, Ries LA. Cancer in older persons. Cancer 1994;74:1995-2003.